기업
pH Pharma, positive P2b results for drug candidate for normal tension glaucoma treatment at the APAO 2019
바이오스펙테이터 Sungmin Kim 기자
PHP-201 demonstrated superiority to placebo for the effect of lowering intraocular pressure (IOP) in patients with normal tension glaucoma
pH Pharma Co., Ltd. presented positive results of phase 2 clinical study of PHP-201, a new drug candidate for treatment of glaucoma, at the 2019 Asia-Pacific Academy of Ophthalmology (APAO 2019) on March 9th in Bangkok, Thailand.
The phase 2 clinical trial entitled “Double-masked, Randomized, Dose-Response of Phase 2 Study of PHP-201 in patients with Normal Tension Glaucoma” was presented by Dr. Ki Ho Park, chairman of ophthalmology at Seoul National University and principal investigator of the trial. Dr. Park was awarded Best Scientific Paper Award at APAO 2019.
"PHP-201 demonstrated superiority to placebo for the effect of lowering intraocular pressure (IOP) in patients with normal tension glaucoma," said Dr. Park. “In addition, the incidence of conjunctival hyperemia was much lower than currently available drugs, and no significant side effects were observed." Conjunctival hyperemia is usually one of the most common side effects of eye drops for glaucoma treatment.
Normal tension glaucoma is a form of glaucoma in which damage occurs to the optic nerve without eye pressure exceeding the normal range. Currently, there are no drugs specifically developed for the treatment of normal tension glaucoma.... <계속>
